Huakang Biomedical Holdings Company Limited (HK:8622)

:8622

8622

Huakang Biomedical Holdings Company Limited

RESEARCH TOOLSreports

Huakang Biomedical Holdings Company Limited (8622) Price & Analysis

0 Followers

8622 Stock Chart & Stats

HK$0.42

HK$0.01(7.32%)

At close: Jan 09 4:00 PM EST

HK$0.42

HK$0.01(7.32%)

Day’s Range― - ―

52-Week RangeHK$0.29 - HK$0.75

Previous CloseN/A

Volume952.00K

Average Volume (3M)2.14M

Market Cap

HK$177.84M

Enterprise ValueHK$130.47M

Total Cash (Recent Filing)HK$36.73M

Total Debt (Recent Filing)HK$6.42M

Price to Earnings (P/E)―

Beta0.43

Next Earnings

Aug 14, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding515,472,000

10 Day Avg. Volume1,472,000

30 Day Avg. Volume2,141,866

Financial Highlights & Ratios

PEG Ratio0.43

Price to Book (P/B)1.26

Price to Sales (P/S)2.68

P/FCF Ratio-13.45

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthA very high equity ratio and minimal leverage provide durable financial flexibility. This conservative capital structure reduces refinancing risk, supports continued operations during losses, and gives management time to execute operational fixes or strategic investments over the next several months.

High Gross MarginA stable ~67% gross margin indicates core products have strong production economics or pricing power. That margin cushion means improvements in SG&A or scale can more readily translate into operating leverage and potential future profitability once cost inefficiencies are addressed.

Consistent Revenue BaseStable revenue provides a reliable operating base to pursue efficiency gains. Even with modest growth, predictable sales reduce execution risk and allow management to focus on margin recovery and cash conversion initiatives that can materially improve fundamentals over a multi-month horizon.

Bears Say

Negative ProfitabilityPersistent operating losses and negative EBIT/EBITDA margins show the business is not currently generating operating profits. That undermines internal reinvestment capacity and shareholder returns, and requires sustained turnaround efforts to restore durable profitability.

Weak Cash GenerationNegative operating and free cash flow indicate the company is burning cash despite reported revenues. Poor cash conversion limits funding for capex, R&D or working capital and may force reliance on external financing if not corrected, stressing liquidity over the medium term.

Minimal Growth & Negative ROEVery low revenue growth coupled with negative ROE signals the company is not generating shareholder returns or expanding its top line meaningfully. Without clear revenue acceleration, the firm may struggle to leverage its margin profile into sustainable profitability.

8622 FAQ

What was Huakang Biomedical Holdings Company Limited’s price range in the past 12 months?

Huakang Biomedical Holdings Company Limited lowest stock price was HK$0.28 and its highest was HK$0.75 in the past 12 months.

What is Huakang Biomedical Holdings Company Limited’s market cap?

Huakang Biomedical Holdings Company Limited’s market cap is HK$177.84M.

When is Huakang Biomedical Holdings Company Limited’s upcoming earnings report date?

Huakang Biomedical Holdings Company Limited’s upcoming earnings report date is Aug 14, 2026 which is in 130 days.

How were Huakang Biomedical Holdings Company Limited’s earnings last quarter?

Huakang Biomedical Holdings Company Limited released its earnings results on Mar 27, 2026. The company reported -HK$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.006.

Is Huakang Biomedical Holdings Company Limited overvalued?

According to Wall Street analysts Huakang Biomedical Holdings Company Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Huakang Biomedical Holdings Company Limited pay dividends?

Huakang Biomedical Holdings Company Limited does not currently pay dividends.

What is Huakang Biomedical Holdings Company Limited’s EPS estimate?

Huakang Biomedical Holdings Company Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Huakang Biomedical Holdings Company Limited have?

Huakang Biomedical Holdings Company Limited has 515,472,000 shares outstanding.

What happened to Huakang Biomedical Holdings Company Limited’s price movement after its last earnings report?

Huakang Biomedical Holdings Company Limited reported an EPS of -HK$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.333%.

Which hedge fund is a major shareholder of Huakang Biomedical Holdings Company Limited?

Currently, no hedge funds are holding shares in HK:8622

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Huakang Biomedical Holdings Company Limited Stock Smart Score

Neutral

Technicals

Fundamentals

Return on Equity

-8.95%

Trailing 12-Months

Asset Growth

1.90%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Huakang Biomedical Holdings Company Limited

Huakang Biomedical Holdings Company Limited (8622) is a biotechnology company focused on the research, development, and commercialization of innovative medical products and services. The company primarily operates in the healthcare sector, specializing in diagnostics and therapeutics that cater to various medical needs. Its core product offerings include advanced diagnostic kits, medical devices, and healthcare solutions aimed at enhancing patient outcomes and improving healthcare efficiency.